Susquehanna International Group
RVNC

Susquehanna International Group’s Revance Therapeutics, Inc. RVNC Stock Holding History

Susquehanna International Group’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-99,900
Closed -$304K – 13772
2024
Q4 		$304K Sell
99,900
-30,000
-23% -$131K ﹤0.01% 9809
2024
Q3 		$674K Buy
129,900
+53,000
+69% +$263K ﹤0.01% 7748
2024
Q2 		$198K Sell
76,900
-113,800
-60% -$389K ﹤0.01% 10372
2024
Q1 		$938K Sell
190,700
-158,000
-45% -$935K ﹤0.01% 7072
2023
Q4 		$3.07M Buy
348,700
+255,800
+275% +$2.1M ﹤0.01% 4537
2023
Q3 		$1.07M Buy
92,900
+12,200
+15% +$235K ﹤0.01% 6493
2023
Q2 		$2.04M Sell
80,700
-180,200
-69% -$5.61M ﹤0.01% 5118
2023
Q1 		$8.4M Sell
260,900
-374,700
-59% -$11.7M ﹤0.01% 2703
2022
Q4 		$11.7M Buy
635,600
+353,200
+125% +$8.08M ﹤0.01% 2068
2022
Q3 		$7.63M Buy
282,400
+196,200
+228% +$3.98M ﹤0.01% 2536
2022
Q2 		$1.19M Sell
86,200
-67,600
-44% -$1.04M ﹤0.01% 6103
2022
Q1 		$3M Buy
153,800
+80,000
+108% +$1.21M ﹤0.01% 4623
2021
Q4 		$1.2M Buy
73,800
+14,500
+24% +$242K ﹤0.01% 6789
2021
Q3 		$1.65M Buy
59,300
+3,700
+7% +$106K ﹤0.01% 6252
2021
Q2 		$1.65M Sell
55,600
-106,000
-66% -$3.06M ﹤0.01% 6381
2021
Q1 		$4.52M Buy
161,600
+99,400
+160% +$2.75M ﹤0.01% 4105
2020
Q4 		$1.76M Sell
62,200
-91,700
-60% -$2.38M ﹤0.01% 5359
2020
Q3 		$3.87M Buy
153,900
+31,500
+26% +$826K ﹤0.01% 3427
2020
Q2 		$2.99M Buy
122,400
+104,700
+592% +$2.07M ﹤0.01% 3810
2020
Q1 		$262K Sell
17,700
-21,600
-55% -$447K ﹤0.01% 8234
2019
Q4 		$638K Buy
39,300
+25,800
+191% +$400K ﹤0.01% 6459
2019
Q3 		$176K Sell
13,500
-3,200
-19% -$39.1K ﹤0.01% 9213
2019
Q2 		$217K Sell
16,700
-6,500
-28% -$81.9K ﹤0.01% 8983
2019
Q1 		$366K Buy
23,200
+7,800
+51% +$135K ﹤0.01% 6863
2018
Q4 		$310K Sell
15,400
-5,300
-26% -$117K ﹤0.01% 6939
2018
Q3 		$514K Sell
20,700
-12,200
-37% -$332K ﹤0.01% 6465
2018
Q2 		$903K Sell
32,900
-40,900
-55% -$1.23M ﹤0.01% 5565
2018
Q1 		$2.27M Buy
73,800
+32,700
+80% +$1.05M ﹤0.01% 3685
2017
Q4 		$1.47M Buy
41,100
+24,700
+151% +$709K ﹤0.01% 4501
2017
Q3 		$452K Sell
16,400
-3,200
-16% -$77.6K ﹤0.01% 6690
2017
Q2 		$517K Buy
19,600
+900
+5% +$20.1K ﹤0.01% 6589
2017
Q1 		$389K Buy
+18,700
New +$384K ﹤0.01% 6942
2016
Q3 		– Sell
-14,800
Closed -$201K – 9178
2016
Q2 		$201K Sell
14,800
-6,100
-29% -$108K ﹤0.01% 7601
2016
Q1 		$365K Sell
20,900
-45,600
-69% -$928K ﹤0.01% 6929
2015
Q4 		$2.27M Buy
66,500
+32,900
+98% +$1.14M ﹤0.01% 3778
2015
Q3 		$1M Buy
+33,600
New +$1.02M ﹤0.01% 5758
2015
Q2 		– Sell
-16,400
Closed -$340K – 10537
2015
Q1 		$340K Buy
+16,400
New +$283K ﹤0.01% 7748

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Susquehanna International Group's RVNC Position: Q1 2025 in Review

Susquehanna International Group sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 303,073 shares — an estimated $921K sold.

Susquehanna International Group first reported a position in RVNC in Q2 2014 and held it in 32 quarters. The position peaked at $6.44M in Q4 2017. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Susquehanna International Group reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Susquehanna International Group sold 303,073 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $921K.
  • Susquehanna International Group first reported a position in Revance Therapeutics, Inc. in Q2 2014 and held it in 32 quarters.
  • Susquehanna International Group's Revance Therapeutics, Inc. position peaked at $6.44M in Q4 2017.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.